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Patient safety after partial and total knee replacement
More than 90 000 people in the UK had knee replace-
ments in 2012, according to the National Joint Registry 
of England and Wales (NJR).1 The human cost of 
this expensive surgery is addressed in two articles in 
The Lancet2,3 that question conclusions from the NJR, 
with major consequences for patient safety and the 
knee replacement industry.
The indications for knee replacement remain 
poorly deﬁ ned: a patient with a small wear patch 
seen on MRI is given the same diagnosis as someone 
whose knee is severely damaged. Both are told they 
have osteoarthritis. International Classiﬁ cation 
of Diseases-10 labels osteoarthritis of the knee as 
gonarthrosis, M17.1, allowing no separation into 
compartments, and no classiﬁ cation of severity. 
So, despite being localised to one compartment in 
most people,4 because of poor diagnostic criteria, 
knee osteoarthritis can be validly approached with 
two diﬀ erent philosophies. Surgeons who deem knee 
osteoarthritis a disease excise the entire joint, thereby 
curing the disease and substituting a total knee 
replacement (TKR). Alternatively, those who deem 
it to be predictable wear do the smaller operation of 
partial, or unicompartmental knee replacement (UKR), 
relining the part that is worn, preserving the rest of the 
joint surfaces, and, importantly, the anterior cruciate 
ligament. In TKR, this important structure is routinely 
excised, which results in reduced ability to walk,5 
explaining perhaps why TKR is less eﬀ ective than is 
total hip replacement,6 and why life expectancy might 
also be aﬀ ected.7 For patients undergoing either TKR or 
UKR, if done well, the probability is that this is the last 
operation that they will need in their lifetime,8 as results 
from hundreds of thousands of patients now enrolled 
into national joint registries around the world conﬁ rm.
Unlike tumour registries, which have strict diagnostic 
inclusion criteria and use death as an endpoint, joint 
registries are focused on the outcome of the device: 
anyone with any amount of joint damage can be 
admitted, only device-related surgical procedures are 
reported as failures, and death is counted as a success. 
Because arthrosis is closely related to ageing, the many 
patients who have died with no need for revision surgery 
stretch the use of so-called survivorship statistics when 
reporting the survival of the implant, not the patient.9
The NJR now has more than 500 000 knee 
replacements registered, making it the world’s largest 
registry, so conclusions from it should have a global 
impact. Set up to give warning of poorly performing 
devices, with operations leading to exchange of device 
as the main focus, the registry is now used to compare 
TKR with UKR. This focus can lead to perverse results: 
a joint replacement with a problem that can be ﬁ xed, 
curing the pain and restoring the patient’s quality of life, 
is a failure owing to its revision, whereas a painful joint 
replacement that cannot be revised, condemning the 
patient to a lifetime of stiﬀ ness and pain, is recorded 
as a success in registry terms.10 Thus, TKRs are reported 
as successful despite the fact that 25% are no better or 
even worse after surgery.11 On the basis of revision rates 
alone, registry data continue to encourage surgeons to 
concentrate on TKR, and avoid UKR.12–15
The two Lancet papers look at the patients who have 
had knee replacements rather than their prostheses. Linda 
Hunt and colleagues2 undertook a multivariate analysis 
of 467 779 cases from the NJR. They linked the national 
Hospital Episode Statistics (HES) with NJR data, in an 
observational study assessing 45-day mortality associated 
with knee arthroplasty to treat osteoarthritis. In their 
analysis, 1183 patients died within 45 days of surgery 
during the 8-year study period. Mortality decreased with 
time; from 0·37% in 2003 to 0·20% in 2011, making knee 
surgery safer than hip replacement, which they reported 
on last year.9 They did, however, note a substantial 
diﬀ erence in risk of perioperative death dependent on 
the type of procedure: the smaller, cheaper operation of 
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UKR was associated with substantially lower mortality 
than was TKR (hazard ratio [HR] 0·32, 95% CI 0·19–0·54). 
Despite this ﬁ nding, Hunt and colleagues stop short of 
commending UKR. Perhaps this absent recommendation 
was to avoid conﬂ ict with the stream of registry 
publications promoting TKR over UKR, with revision as 
the only indicator of failure.13–17
Alexander Liddle and colleagues3 also link HES and NJR 
data. In addition to mortality, they look at all rates of 
reoperation, not just revision, and also complications, 
readmission to hospital, and length of hospital stay. A 
study group of more than 101 330 matched cases was 
assembled with propensity score matching to include 
three TKRs for every UKR (25 334 UKRs were matched 
to 75 996 TKRs), ensuring the best possible use of data. 
They report early and late complications separately. 
Risk of early death after surgery was again signiﬁ cantly 
lower for UKR than for TKR at all timepoints (30 day: 
HR 0·23, 95% CI 0·11–0·50; 8 year: 0·85, 0·79–0·92). To 
avoid one death by 4 years after surgery, the number 
needed to switch from TKR to UKR is 93, dropping to 
62 at 8 years.
Death is not only a very ﬁ rm and clinically important 
endpoint, but also a surrogate for more common risks 
of intraoperative complications, stroke, myocardial 
infarction, thrombo embolism, blood transfusion, and 
admission to critical care—all much more common 
after TKR than after UKR. Implant-related complications 
resulting in operations occur later and were substantially 
more common after UKR (subhazard ratio [SHR] 2·12, 
95% CI 1·99–2·26) at 8 years.3 These problems, which 
were mainly loosening and implant failure, were usually 
treated by a primary TKR. When the same problems of 
loosening or implant failure resulted in reoperation after 
TKR, they were often treated by larger so-called revision 
devices involving stems and augments. Infection, which 
is the most serious and costly local complication, was 
half as likely after UKR than after TKR in this large analysis 
(0·50, 0·38–0·66). In neither study was information 
available about thresholds for reoperation. By combining 
these datasets with outcome scores and costs, a formal 
cost -eﬀ ectiveness analysis shows that UKR is a cost- 
eﬀ ective option, despite the revision rate.18
What can be drawn from these two large studies? 
When measured in terms of risk of perioperative death 
or serious morbidity, UKR is unequivocally safer than 
TKR. This simple message should be of great interest 
to patients and the clinical commissioning groups 
and insurers who pay for health care. This ﬁ nding is at 
odds with the industry-funded NJR that suggests that 
UKR should be restricted, if not abandoned, for its high 
revision rate,16 despite improved postoperative scores.1
Arguments of this sort are not new to surgery. For 
women with operable breast cancer, for example, 
lumpectomy and radiotherapy oﬀ ered substantial 
advantages, yet were met with ﬁ erce resistance from 
surgeons and centres promoting radical mastectomy. 
The strategy of radical mastectomy for all malignant 
breast disease was laid to rest 25 years ago with trial 
results showing no survival beneﬁ t over lumpectomy, 
despite a substantial reoperation rate for local recurrence 
in the conservative surgery group.19 A randomised 
trial of partial versus radical genuectomy (TKR has 
been described as internal amputation of the knee) 
reported at 5, 10, and 15 years showed that the smaller 
operation of UKR was not functionally inferior at any 
timepoint.20 Although in breast cancer survival rightly 
refers to the patient, and her breast, in the looking-glass 
of world of implant registries death is a success, and 
only implant revision counts as a failure. The fairly high 
mortality in the mainly older population who require 
knee replacement makes the use of survival statistics 
challenging when reporting on prostheses, not patients.9
So what prevents the smaller, cheaper, and safer 
operation becoming adopted widely? UKR is a complex 
operation to learn, yet, in the UK, surgeons and 
hospitals are paid less for it by private insurers, with 
NHS reimbursement varying depending on what code 
is used. Today, many surgeons in the UK have agreed 
to have their activity and mortality statistics in the 
public domain as part of the government’s focus on 
patient safety. The NJR goes further though. It reports 
surgeons to the chief executives of their hospitals, not 
for excessive mortality, strokes, myocardial infarctions, 
or infections, but for having a revision rate that is high 
for TKR, but could be normal for UKR perhaps simply 
because this small operation is rather easier to ﬁ x, if 
a problem arises. These two papers should provoke a 
review of knee arthroplasty by policy makers worldwide. 
Substantial public and private savings are possible: of the 
90 000 knee replacements reported in 2012 in England 
and Wales, only 8% were UKR.1 If only half of those 
eligible were oﬀ ered the more conservative procedure of 
UKR, the NHS could save an estimated £70 million every 
For more on surgeons see 
http://www.
njrsurgeonhospitalproﬁ le.org.uk
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Do we need to know whether nitrous oxide harms patients?
In The Lancet, Paul Myles and colleagues1 investigate 
the association between nitrous oxide exposure 
and cardiovascular complications such as non-fatal 
myocardial infarction, stroke, pulmonary embolism, 
cardiac arrest, and death, within 30 days of surgery, 
in patients with known or suspected coronary artery 
disease having major non-cardiac surgery under general 
anaesthesia. The rationale for this large, multicentre 
study, which involved more than 7000 patients from 
45 centres, was the observation that short-term exposure 
to nitrous oxide led to signiﬁ cant increases in plasma 
homocysteine.2 Hyperhomocysteinaemia impairs arterial 
ﬂ ow and has been associated with cardiovascular disease.3 
The authors report that nitrous oxide did not increase 
year immediately on operative costs alone,18,21 and, on 
the basis of these two papers, there would be 170 fewer 
postoperative deaths annually, and many hundreds of 
fewer strokes, myocardial infarctions, and infections.
While perverse incentives remain in place, the TKR 
industry will continue to grow steadily encouraged 
by statistics based upon revision rates alone. With 
hundreds of lives and hundreds of millions of pounds at 
stake every year, a change in knee replacement strategy 
deserves consideration today, as it did with mastectomy 
25 years ago.
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